Engflag

Eurocam

Quick links to important sections

Eurocam

Eurocam_FR

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Eurocam

Quick Facts: Eurocam (Meloxicam)

Property Description
Active Ingredient Meloxicam
Pharmacological Class Nonsteroidal Anti-inflammatory Drug (NSAID)
Forms Available Tablet, Capsule, Solution for Injection
Origin Synthetic Compound (Oxicam group)
Primary General Action Anti-inflammatory, Analgesic, Antipyretic

What Type of Medicine is Eurocam?

Eurocam is a prescription medicine and is broadly categorized as a Nonsteroidal Anti-inflammatory Drug (NSAID). Its active agent, Meloxicam, is specifically identified as an enolic acid derivative within the oxicam chemical group, confirming its synthetic origin. This classification defines Eurocam as an effective anti-inflammatory agent and analgesic used in systemic therapy. Furthermore, Meloxicam is clinically recognized for its selective inhibition of the Cyclooxygenase-2 (COX-2) enzyme, differentiating its mechanism from older, less selective NSAIDs by focusing on the enzymes associated with the inflammatory pathways in adult patients.

Composition, Origin, and Available Forms

The therapeutic effect of Eurocam is due entirely to its single active ingredient, Meloxicam. As a therapeutic agent, Eurocam is supplied in several fundamental dosage forms to accommodate various needs. The common formulations include the oral solid forms, such as the tablet and capsule, alongside a clear solution for injection. This parenteral formulation allows for administration via the Intravenous (IV) route, while the oral forms are taken via the oral route, with each containing Meloxicam within either a solid matrix or an aqueous/hydroalcoholic solution base. The availability of multiple forms is essential for providing continuous anti-inflammatory therapy.

General Purpose and Physiological Role

The overall purpose of Eurocam is to manage and mitigate the three key physiological symptoms associated with inflammation: pain, swelling, and fever. By inhibiting the body’s production of inflammation-causing substances, the medicine provides a potent anti-inflammatory effect. Clinical data confirm that Meloxicam exhibits substantial anti-inflammatory and pain-relieving effects. This means the medicine is verified to ease pain and reduce swelling associated with ongoing inflammation, which is a typical requirement for managing chronic joint conditions. This action, combined with its strong analgesic effect (pain relief) and complementary antipyretic effect (fever reduction), establishes Eurocam as a core agent for the management of chronic tissue distress and discomfort.

What side effects are possible with Eurocam?

Official Adverse Reactions and Safety Profile

The safety characteristics of Eurocam (Meloxicam) are established through regulatory review and classified by frequency and affected organ system. This information is derived from official government documents, such as the FDA Prescribing Information and the European Summary of Product Characteristics (SmPC).

Frequency-Classified Effects

Classification Examples of Documented Adverse Reactions
Most Common (ge5%) Diarrhea, upper respiratory tract infections, dyspepsia (indigestion), and influenza-like symptoms.
Common (ge1% to lt5%) Nausea, abdominal pain, vomiting, constipation, headache, dizziness, and fluid retention (edema).

Serious Adverse Reactions (SARs)

Official labeling documents risks common to the Nonsteroidal Anti-inflammatory Drug (NSAID) class:

  • Cardiovascular Thrombotic Events: An increased risk of serious, potentially fatal events, including myocardial infarction and stroke, is documented. This risk may occur early in treatment and may increase with the duration of use.
  • Gastrointestinal Adverse Events: There is an increased risk of serious GI events, including bleeding, ulceration, and perforation of the stomach or intestines, which can occur without warning symptoms.
  • Other Serious Events: Severe skin reactions, such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), are also officially noted in the regulatory text.

Population-Specific and Contextual Safety Notes

Older adults are designated as a population at greater risk for serious gastrointestinal events. The medicine is contraindicated in the setting of peri-operative pain for Coronary Artery Bypass Graft (CABG) surgery and in patients with known severe allergies to aspirin or other NSAIDs. Furthermore, avoidance is recommended from approximately 30 weeks of pregnancy due to documented fetal risks.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Eurocam (Meloxicam) may result in an extreme presentation of its established adverse effects, though many individuals remain asymptomatic or present only with minor symptoms. Officially documented initial manifestations typically involve nausea, vomiting, epigastric pain, drowsiness, and lethargy.

However, a significant overdose can lead to severe, potentially life-threatening outcomes affecting multiple organ systems. These serious manifestations documented in regulatory sources include major gastrointestinal bleeding or perforation, acute renal failure, convulsions (seizures), respiratory depression, and serious cardiovascular complications such as collapse or cardiac arrest.

Immediate medical attention is required for any suspected overdose. Emergency services must be contacted if the patient exhibits severe signs like unresponsiveness, difficulty breathing, or seizures. No specific antidote is known for meloxicam toxicity. Management, as directed by official guidance, is symptomatic and supportive treatment, which may involve gastric lavage, activated charcoal, or the administration of cholestyramine to enhance drug elimination. Patients who are elderly or have pre-existing renal or hepatic impairment are identified as being at increased risk for severe outcomes and require close hospital monitoring.

Therapeutic Uses of Eurocam

Quick Facts: Eurocam Therapeutic Areas

  • Chronic Pain Management: Intended to help manage persistent discomfort associated with inflammatory conditions.
  • Joint Function: Supports maintaining the mobility of joints in individuals with long-term stiffness.
  • Inflammatory Support: Used to address symptoms linked to the body's inflammatory processes.

Eurocam is an available therapeutic option for individuals seeking support in managing the symptoms of certain chronic inflammatory conditions. This medication is primarily indicated for the supportive care of long-term joint discomfort and the stiffness that often accompanies these diagnoses. Clinical use suggests that the compound may help to relieve joint discomfort and contribute to maintaining joint mobility.

The therapy is intended to help manage the progression of symptoms associated with chronic inflammation, allowing users to address their overall health and well-being. The product is not intended to treat, cure, or prevent any disease.

Regulatory References

  1. EMA therapeutic overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Eurocam?

The eligibility for Eurocam (Meloxicam) is strictly defined by governmental regulatory documentation, outlining specific populations that are permitted, restricted, or absolutely prohibited from using the medicine.

Populations for whom use is Contraindicated:

  • Patients with known hypersensitivity to meloxicam or other NSAIDs (e.g., aspirin-sensitive asthma).
  • Individuals with an active or history of recurrent peptic ulcer or GI bleeding/perforation.
  • Those with severely impaired liver function or non-dialysed severe renal failure.
  • Women in the third trimester of pregnancy (starting approx 30 weeks gestation) and patients undergoing Coronary Artery Bypass Graft (CABG) surgery.

Age-Related Eligibility:

  • Use is generally approved for adults. While approved for Juvenile Rheumatoid Arthritis in children 2 years of age and older (US Labeling), it is generally contraindicated in adolescents under 16 years (EU SmPC).
  • Older adults (ge 65 years) may use the medicine but require caution and close supervision.

Condition-Specific Restrictions: Use is restricted or requires caution for populations like those on hemodialysis (limited to 7.5 mg maximum daily dose) and patients with a history of uncontrolled heart failure or hypertension. Use is generally not recommended while breastfeeding.

What should I know about interactions with other medicines?

Interaction scope

Medicinal product categories with documented interactions: NSAIDs, Oral Anticoagulants, Corticosteroids, Antihypertensives (ACE Inhibitors, ARBs), Diuretics, Lithium, Methotrexate, Cyclosporine, SSRIs, and SNRIs.

Specific interacting medicines (if explicitly listed): Warfarin, Furosemide, Lithium, Methotrexate, and Cholestyramine.

Mechanistic basis of interactions (only if stated in label): Cytochrome P450 2C9 (CYP2C9) metabolism; interference with platelet function; inhibition of natriuretic effects; interference with renal clearance.

Timing-based interaction rules (if applicable): No mandatory timing separation rules are explicitly documented for co-administration with meals or antacids.

Population-specific interaction notes (if applicable): Elderly patients have a greater documented risk for severe gastrointestinal (GI) events and renal deterioration when combined with certain medicines; maximum dosage is restricted for patients on hemodialysis.

Interaction-related restrictions: Prohibition of co-administration with other NSAIDs (including analgesic-dose Aspirin); formal contraindication for peri-operative pain management following Coronary Artery Bypass Graft (CABG) surgery; restriction of Meloxicam oral suspension with Sodium Polystyrene Sulfonate.

Interaction classifications (high-level)

Interaction severity classification (as defined in official documents): Contraindicated, Not Recommended, Risk of Serious Bleeding/Ulceration, Risk of Toxicity, Reduced Efficacy.

Regulatory basis: EMA SmPC and FDA Prescribing Information.

Interaction-context constraints (as defined in official documents): Alcohol consumption is documented to increase the risk of GI bleeding; Antacids show no clinically significant interaction; a high-fat meal may increase the drug's peak concentration (C max).

Resulting interaction structure

Official interaction statements:

  • Co-administration with other NSAIDs is prohibited due to synergistic toxicity risk, including with analgesic-dose Aspirin.
  • The drug increases the risk of serious bleeding when combined with Oral Anticoagulants (e.g., Warfarin) or SSRIs/SNRIs.
  • Meloxicam can increase the plasma levels of Lithium and Methotrexate by reducing their clearance.
  • The medicine reduces the antihypertensive effect of ACE Inhibitors and ARBs, while also reducing the natriuretic effect of Diuretics.
  • Metabolism is primarily mediated by CYP2C9, and individuals classified as poor metabolizers may experience higher systemic concentrations.

Connection to the overall interaction profile (3 sentences):

Regulatory documents define Eurocam's interaction profile through domains of synergistic toxicity, modulation of drug efficacy, and pharmacokinetic alteration of co-administered drugs. This framework establishes formal constraints, such as prohibiting specific drug class combinations and noting conditions, like alcohol consumption or advanced renal impairment, that amplify interaction severity. The profile confirms that co-administration must be managed according to the potential for severe adverse events, rather than minor effects.

Mechanism of Action

The Core Mechanism: Preferential Targeting of COX-2

Eurocam's mechanism initiates at the molecular level by preferentially inhibiting the Cyclooxygenase-2 (COX-2) enzyme. This targeted action blocks the enzyme's ability to convert Arachidonic Acid into pro-inflammatory signaling molecules, primarily Prostaglandin E2 (PGE2). This modulation is central to reducing the intensity of signaling associated with tissue damage.

Systemic Modulation of Pain and Temperature Signals

The reduction in PGE2 acts across key systems: peripherally, it decreases the sensitization of nociceptors (pain receptors) to stimuli. Centrally, the drug's mechanism lowers PGE2 concentration in the hypothalamus, the brain's thermostat. These combined physiological adjustments contribute to modulating the responsiveness of afferent nerve endings and resetting the elevated thermal set-point.

Mechanistic Boundaries and Selectivity Trade-Offs

The mechanism is defined by its preferential, rather than absolute, COX-2 inhibition, meaning a small degree of COX-1 inhibition remains. This less selective action interferes with constitutive prostaglandin production required for homeostatic maintenance. Furthermore, the drug does not engage the separate Lipoxygenase (LOX) pathway, which continues to generate inflammatory mediators.

Dosage and Administration Information

The official use of Eurocam (Meloxicam) is defined by guidelines concerning the administration route, dosage, and scheduling, ensuring consistent and appropriate application.

Instruction Map: How to use Eurocam — Official Administration Guidelines

Administration Scope

Instruction Category Official Statement
Route of Administration The medicine is approved for both Oral intake (tablet, capsule, suspension) and Intravenous (IV) injection (solution for injection).
Dosing Schedule Maintenance therapy typically starts at 7.5 mg once daily, with a maximum daily dose of 15 mg for most oral forms. The IV dose for acute pain is established as 30 mg once daily.
Timing in relation to meals (if applicable) Oral forms may be taken with or without food, although some information specifies intake during a meal with water.
Preparation Requirements (if applicable) The oral suspension must be gently shaken before use. The IV solution is administered as a bolus over 15 seconds.
Age-Group Administration Rules The maximum oral dose for hemodialysis patients is restricted to 7.5 mg daily. A lower dose is often recommended for older adults in long-term treatment.
Missed-Dose Rules If a dose is missed, instructions are to take the next dose at the regularly scheduled time; a double dose must not be used to compensate.
Special Procedural Conditions The use of the medication is governed by the principle of using the lowest effective dose for the shortest possible duration.

Instruction Classifications (High-Level)

Classification Official Pattern/Rule
Administration Method Type Oral and Intravenous
Frequency Pattern Once daily (q.d.)
Basis of Use Standardized information for professional administration.
Use-Context Constraints Lowest dose, shortest duration principle.

Resulting Procedural Structure

Official step sequence:

  • The appropriate route and form is selected (e.g., Oral tablet or IV solution).
  • The dose is determined based on the maximum daily limit (e.g., 15 mg oral or 30 mg IV).
  • The dose is administered once daily following the specific intake conditions (e.g., with food or bolus injection over 15 seconds).

Connection to the overall use protocol (2–4 sentences): The administration protocol for Eurocam is characterized by a strict once-daily schedule and a mandatory maximum daily dose constraint. This structure standardizes the application across different formulations, guiding the proper use by detailing the precise route, frequency, dose limits, and preparation steps as established for this medication.

Recent Clinical Evidence

Research evidence / Overview of Studies for Eurocam

Evidence for use in Osteoarthritis (OA)

Short-term randomized controlled trials (RCTs) were applied in studies examining Eurocam's use in osteoarthritis. These studies were designed to measure changes in outcomes related to physical discomfort and daily functioning in adult patients with confirmed OA, involving study populations with confirmed OA of the hip or knee.

Studies conducted during periods of increased symptom activity reported that the measured outcomes in the group taking specific doses of Eurocam were associated with different patterns compared to the group receiving an inactive substance (placebo). Follow-up durations were limited in the initial efficacy trials, and there is limited information for long-term outcomes concerning continued maintenance of functional status.

Evidence for use in Rheumatoid Arthritis (RA)

The evidence base for Eurocam in rheumatoid arthritis relies heavily on randomized controlled trials. These studies explored short-term symptom changes in adult patients with active RA. Research examined outcomes related to systemic or functional imbalance, including the reduction in the number of painful joints and swollen joints, alongside global assessments of disease activity.

Findings from some short-term placebo-controlled trials indicated that for certain tested doses, reported changes in pain and patient-assessed disease activity were associated with Eurocam use. Evidence derived from these studies focused on symptomatic outcomes and did not cover long-term changes in underlying disease progression, such as structural joint damage.

Research Gaps and What Remains Uncertain

The follow-up durations were limited in the most rigorous efficacy trials, meaning long-term effects are not fully established. Similarly, comparative evidence is sometimes lacking against other therapeutic agents used for conditions like RA and AS. Data for certain groups remain insufficient; for example, evidence for certain populations defined by specific comorbidities remains limited compared to data from generally healthy study populations. Overall, the research provides context but not individual predictions, and findings describe group patterns, not personal outcomes.

Key Studies & References

  1. PUBLIC ASSESSMENT REPORT of the Medicines Evaluation Board in the Netherlands Meloxicam Aurobindo 7.5 mg and 15 mg, tablets
  2. Study Details | NCT00279747 | A One Year Double-blind Trial to Investigate the Efficacy and Safety of Meloxicam Oral Suspension in Juvenile Rheumatoid Arthritis (JRA/JIA) | ClinicalTrials.gov

Frequently Asked Questions (FAQ)

Common questions about Eurocam (FAQ)

Q: Is Eurocam the same type of medicine as [similar common drug name]?

Eurocam is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). Official documents characterize its active ingredient, Meloxicam, by its preferential inhibition of the Cyclooxygenase-2 (COX-2) enzyme. This selective action defines how it is classified within the broader category of anti-inflammatory medicines.

Q: How quickly does Eurocam start working?

Clinical information indicates that the first pain-relieving effects may be observed within the first day of treatment for some patients. The full therapeutic effect for chronic conditions is typically noted over a longer period.

Q: How long does the effect of Eurocam last?

The medicine is generally prescribed for once-daily use. The duration of the medicine’s elimination is related to its half-life, which in adults is typically reported in official documents to range from 15 to 20 hours.

Q: What does the packaging insert say about stopping Eurocam?

The guidance emphasizes that the medicine should be used at the lowest effective dose for the shortest duration. Official guidance documents indicate that sudden discontinuation is not generally recommended. Stopping the medicine may be associated with the return of the symptoms for which it was originally prescribed.

Q: What is the difference between the available strengths of Eurocam?

Clinical studies examined different strengths and indicated that both were associated with a statistically significant improvement in measured outcomes compared to an inactive substance (placebo). The choice of strength is defined by the official prescribing information for the specific condition being addressed.

Q: How does Eurocam's benefit/risk profile compare to other drugs in its class?

The medicine’s preferential inhibition of the COX-2 enzyme is associated with reduced risk of gastrointestinal irritation compared to nonselective nonsteroidal anti-inflammatory drugs (NSAIDs). Clinical studies have also indicated that its efficacy profile is generally comparable to certain other NSAIDs in treating specific conditions.

Q: Can Eurocam cause tiredness or fatigue?

Official documents note that common adverse reactions include headache and dizziness. Drowsiness or fatigue is not identified as a common or most common side effect in the official product information.

Q: Is Eurocam safe to use if I have kidney issues?

Official guidelines provide specific dosing information for individuals with mild to moderate renal impairment, stating that no change in dose is required. However, use is restricted or contraindicated for individuals with severe, non-dialyzed kidney failure.

Q: Are there any major diet restrictions while taking Eurocam?

Regulatory information indicates the medicine can generally be taken with or without food. No specific major diet restrictions are listed in the official documents.

Q: What happens if I miss a scheduled time to take Eurocam?

Official guidance addresses the management of a missed dose. The documentation states that the next dose should be taken at the regularly scheduled time. A double dose must not be used to compensate for the missed dose.

Q: Can Eurocam affect my sleep patterns?

Official regulatory documents sometimes include 'insomnia,' or trouble sleeping, as a reported adverse reaction.

Q: Can older adults use Eurocam safely?

Official documents define older adults (age 65 and over) as a population requiring caution due to a documented greater risk for serious adverse events, particularly related to the gastrointestinal tract and kidneys. For this population, some documents specify that a lower dose may be used for long-term treatment.

Q: What is the difference between Eurocam and a placebo in clinical trials?

Clinical studies examined tested doses which were associated with a statistically significant improvement in measured outcomes for pain and function when compared to an inactive substance (placebo).

Q: Is Eurocam habit-forming or addictive?

Eurocam is a Nonsteroidal Anti-inflammatory Drug (NSAID). As an NSAID, it is not classified as a controlled substance and is not considered a narcotic.

Q: How is Eurocam eliminated from the body?

The medicine is extensively processed in the liver, primarily by an enzyme system called CYP2C9, into inactive substances called metabolites. These metabolites are then eliminated from the body via both urine and feces.

Q: Do you need a prescription for Eurocam?

Yes, Eurocam is officially classified as a prescription-only medicine.

Q: Are there specific food types that interact with Eurocam?

Official documents note that while the medicine can generally be taken with or without food, administration after a high-fat meal may be associated with an increase in the maximum concentration (C max), or peak level, of the drug in the bloodstream.

Q: Are there any restrictions on driving while using Eurocam?

Regulatory information notes that the medicine may be associated with adverse effects like dizziness or drowsiness. Due to the possibility of these effects, caution is noted in regulatory documents regarding driving or operating machinery.

Q: What is the average time before I might see the full results of Eurocam?

Clinical studies indicate that for chronic conditions like osteoarthritis, improvements in pain and joint function were typically observed within approximately one to two weeks of starting the once-daily regimen.

Q: What are the common misunderstandings about Eurocam?

One common misunderstanding addressed in official information is that Eurocam is sometimes incorrectly assumed to be a narcotic. Its regulatory classification confirms that it is an NSAID, not a narcotic.

Q: Can Eurocam be used by teenagers or children?

Use is authorized for the treatment of Juvenile Rheumatoid Arthritis (JRA) in children aged 2 years and older in some regions (US labeling). However, in other regions (EU SmPC), its use is generally restricted for adolescents under 16 years of age.

Q: What are the main points about who should avoid Eurocam?

Official documents list several conditions where the medicine is considered contraindicated and should be avoided. These conditions include known allergies to NSAIDs, active gastrointestinal bleeding or ulcers, severe liver or kidney failure, and use during the third trimester of pregnancy.

Q: Is it safe to suddenly stop taking Eurocam?

Official guidance documents indicate that sudden discontinuation is not generally recommended. Stopping the medicine may be associated with the return of the symptoms for which it was originally prescribed.

Q: Does taking Eurocam cause weight change?

Fluid retention (edema) is listed as a common adverse reaction in official documents. This can be associated with slight changes in body weight.

Q: Is Eurocam meant to cure a condition or just manage symptoms?

Official information describes the medicine as being used for the symptomatic treatment of specific inflammatory conditions. This means its primary function is to help manage signs and symptoms such as pain and swelling, and it is not intended to alter the course of the underlying disease.

Q: Can Eurocam be used during breastfeeding?

Official regulatory documents state that use of the medicine is generally not recommended during the period of breastfeeding.

How should Eurocam be stored and disposed of?

How to Store and Dispose of Eurocam

Storage Requirements

Eurocam (meloxicam) must be stored strictly according to official regulatory documentation to maintain its stability and effectiveness.

  • Temperature Control: Store the medicine at controlled room temperature, generally defined as between 20 C to 25 C (68 F to 77 F). Brief excursions outside this range are usually permissible.
  • Environmental Protection: Keep the product in its original, tightly closed container to protect it from moisture and light. Specific liquid formulations must not be frozen.
  • Child Safety: It is mandatory to keep this medicine out of the sight and reach of children and away from unsecured locations.

Disposal Instructions

Unused or expired Eurocam must not be disposed of in household waste or poured down the drain. The medicine must be discarded according to local and national regulations, such as returning it to a local collection point or pharmacy take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Eurocam found in:

A-Z Index: